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Flexible bronchoscopy may decrease respiratory
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in focus
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Abstract
Background: Flexible bronchoscopy (FB) is a procedure accepted to be safe in general, with low complication rates
reported. On the other hand, it is known that patients with pre-existing respiratory failure have developed
hypoventilation following FB. In this study the effects of FB on respiratory muscle strength were investigated by
measuring maximum respiratory pressures.
Methods: One hundred and forty patients, aged between 25 and 90 years, who had undergone diagnostic
bronchoscopy between February 2012 and May 2012, were recruited to the study. Pre- and post-procedure
maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were measured. A correlation between
the MIP and MEP changes and patient characteristics and FB variables were investigated.
Results: Significant decreases in both MIP and MEP values were observed following FB (p < 0.001 for both).
Decreases were attributed to the midazolam used for sedation. Significant decreases in respiratory muscle
strengths were observed especially in the high-dose midazolam group, compared to both low-dose and
non-midazolam groups.
Conclusions: It was determined that respiratory muscle weakness may arise post-procedure in patients who have
undergone FB, and this is constitutively related to midazolam premedication. Respiratory muscle weakness might
play a role in potential hypoventilation in critical patients who undergo FB.
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Background
Flexible bronchoscopy (FB) is a procedure that is widely
used in the diagnosis and management of airway and
lung diseases, and is accepted to be safe in general [1].
Data regarding bronchoscopy complications and low
complication rates are mostly obtained from retro-
spective studies. However, the increase in therapeutic
bronchoscopy applications, which are becoming more
and more complex, and the bronchoscopy applications
in risky patient groups cause an increase in complication
rates [2].
Hypoventilation has been shown to develop during
and after the procedure in patients who undergo bron-
choscopy [3,4]. This has mostly been linked to sedative
agents in relevant studies. However, to our knowledge,
the effects of bronchoscopy itself and/or sedative agents
on respiratory muscle strength have yet to be studied.
The aim of this study was to evaluate the effects of
bronchoscopy on respiratory muscle strength, which as
an important role in respiratory function and induction
of cough reflex [5,6].
Methods
Patients
One hundred and forty patients, aged between 25 and
90 years, who had undergone diagnostic bronchoscopy
between February 2012 and May 2012 were recruited to
the study. Patients with hemodynamic instability (heart
rate below 50 bpm or above 120 bpm, systolic arterial
blood pressure below 90 mmHg or above 180 mmHg),
basal oxygen saturation <90%, PaCO2 > 45 mmHg, liver
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or kidney dysfunction, those who were diagnosed
with a neuromuscular disease, had cancer with cachexia,
medium (FEV1 between 50 and 80%), severe (FEV1 be-
tween 30 and 50%) or very severe (FEV1<30%) COPD,
and those who could not cooperate with respiratory
muscle strength test or with benzodiazepine allergy have
not been included into the study. Study protocol was
approved by Selcuk University Selcuklu Medical Faculty
Ethics Committee. Written informed consent was
obtained from all participants.
Bronchoscopy
All bronchoscopy procedures were performed by the
same experienced investigator in accordance with the
international guidelines [7]. In the absence of any con-
traindications, IM atropine (0.01 mg/kg) was given to
the patients half an hour prior to the procedure. 2% lido-
caine was applied topically to the inside of the mouth,
pharynx, upper respiratory airways and endobronchially.
As a routine application at our clinic, IV midazolam was
offered to all patients by the bronchoscopist prior to the
procedure and 1 mg IV midazolam was given to those
who accepted the offer 3 minutes prior to the procedure.
While no additional doses were given to patients who
had adequate sedation during the procedure, additional
doses of 1 mg were given in 2-minute intervals to
patients considered to be in need by the bronchoscopist.
At the end of the study, patients were retrospectively
separated into three groups: no midazolam (Group A),
low-dose midazolam (Group B), and high-dose midazo-
lam (Group C).
2–4 ml/min oxygen supplementation was performed
in all patients, and oxygen flow was increased in case of
hypoxemia. Flumazenil was kept available for suspected
cases of respiratory depression. An IV vascular access
was prepared, and electrocardiogram (ECG), oxygen sa-
turation and non-invasive blood pressure monitoring
were performed throughout the procedure. Total du-
ration of bronchoscopy, midazolam dose and adverse
events during the endoscopic procedure were recorded.
Cardiopulmonary complications observed during the
flexible bronchoscopy were defined as the following:
hypotension (systolic blood pressure (BP) <90 mmHg or
mean arterial blood pressure <60 mmHg), hypertension
(systolic BP >180 mmHg or diastolic BP >90 mmHg),
tachycardia (HR >100/min and/or a variation of >20%
from baseline value), bradycardia (HR <50/min), and
oxygen desaturation (SaO2 decrease <90% for >30s).
Monitoring was continued for 2 hours following the pro-
cedure. 0–100 mm visual analogue scale (VAS) was used
two hours after the flexible bronchoscopy to investigate
the comfort of the procedure. A higher score meant
better satisfaction or less discomfort (0: worst imaginable
health state, 100: best imaginable health state).
Maximum respiratory pressure measurements
A hand-held respiratory pressure meter (Micro RPM;
Micro Medical, Chatham, UK) was used to measure
respiratory muscle strength [8]. Maximal inspiratory
pressure (MIP) was acquired from residual volume (RV)
and the maximal expiratory pressure (MEP) was acquired
from total lung capacity (TLC). Measurements were
taken prior to bronchoscopy before premedication and
after 30 minutes following the procedure by the same
investigator without any knowledge of the clinical condi-
tions of the patients. The operator explained the proced-
ure before beginning and showed the correct manoeuvre.
MIP was measured first, followed by MEP. Patients per-
formed 5 maneuvers in intervals of 1 minute for each
measurement and the highest values (<20% variance)
were recorded [9].
Statistical analyses
Descriptive statistics are shown as mean (±SD) or count
(percentage). T-test was used to compare respiratory
muscle strengths before and after bronchoscopy for all
patients. T-test or One-Way ANOVA were used to com-
pare each variable for the mean MIP and MEP changes.
One-Way ANOVA and Chi-square tests were utilized in
the comparison of continuous and categorical variables
between various midazolam dose groups, respectively.
The post-hoc comparisons of significant difference
between the groups were performed using the Tukey
test. The statistical significance level was set to 0.05.
Results
Bronchoscopies were successfully performed in all of the
140 patients included in the study. As to the midazolam
dosages: 34 patients did not want midazolam adminis-
tration (Group A), 66 were administered 1 mg of mida-
zolam prior to the procedure, and 40 received high
doses (mean, 0.05± 0.03 mg/kg) of midazolam (Group C).
Patient characteristics and complications developed
during the bronchoscopy are presented in Table 1. The
study population mostly comprised middle- and old-
aged males. One third of the patients had mild COPD
and the most common complication observed was
tachycardia. On the contrary, hypertension, bradycardia,
hypotension and desaturation were rarely encountered
complications.
When the overall pre- and post-procedure MIP and
MEP values were compared (73.9 ±24.4 cmH20 vs
68.9 ±25.2 cmH20; 99.9 ±29.8 cmH20 vs. 89.9 ±28.1
cmH20 respectively), significant decreases in both values
were observed (p < 0.001 for both comparisons; Figure 1).
Patients were dichotomized according to median age,
median duration of bronchoscopy, smoking status, and
COPD history in order to determine the variables that
may cause a decrease in respiratory muscle strength. In
Tulek et al. Multidisciplinary Respiratory Medicine 2012, 7:31 Page 2 of 6
http://www.mrmjournal.com/content/7/1/31
addition, the pre- and post-procedure MIP and MEP
values were investigated between the different midazo-
lam dose groups as well. Among these variables, a sig-
nificant difference was determined only in different
midazolam dose groups in terms of Δ MIP and Δ MEP
(Table 2).
The post-hoc analysis in the midazolam groups
revealed no significant difference between the Groups A
and B in terms of Δ MIP (p > 0.05) while Δ MIP was
higher in Group C when compared to Group A
(p < 0.001) and Group B (p < 0.001). There was no sig-
nificant difference between Group A and Group B in
terms of Δ MEP (p > 0.05). Δ MEP was higher in
Group C when compared to Groups A (p = 0.04) and
B (p = 0.05).
The comparison of pre- and post-procedure MIP and
MEP values among different midazolam dose groups
using T-test revealed no significant difference in terms
of MIP measurements in the Groups A and B; however,
there was a significant decrease in post-procedure MEP
values in both groups. Significant decreases in both the
post-procedure MIP and MEP values were determined
in Group C (Table 3).
No significant differences were determined in terms of
age, sex, smoking status, ratio of patients with COPD,
duration of bronchoscopy, and basal MIP/MEP mea-
surements in different midazolam groups. However,
there was a significant difference between the groups in
terms of patient comfort assessed using VAS (p < 0.001),
and while there was no significant difference between
the Groups A and B in the post-hoc test, the VAS scores
of Group C was determined to be higher than the
patients in Group A and Group B (p < 0.001 for both
comparisons; Table 4).
Discussion
In this study, where -to our knowledge- the effects of FB
and premedication on respiratory muscle strengths were
investigated for the first time, it was revealed that mida-
zolam, administered for sedation purposes in bronchos-
copy, might affect negatively the respiratory muscle
strengths, as shown with MIP and MEP measurements.
Flexible bronchoscopy is generally regarded as a
safe procedure [1]. Hypoventilation is one of the most
common complications and many causes of hypoven-
tilation related to FB have been defined. These include
ventilation-perfusion mismatch related to the procedure
itself, upper airway obstruction, sedation-related central
respiratory depression, and increased resistance due to
introduction of bronchoscope into the trachea [3,10]. Our
findings show that sedation-related respiratory muscle
weakness can be included among these mechanisms.
Pulse oxymetry is utilized in many centers for moni-
toring hypoventilation during bronchoscopy. On the
other hand, patients are routinely given oxygen during
FB in many centers. Bronchoscopy guidelines recom-
mend oxygen supplementation to maintain oxygen sa-
turation at a minimum of 90%, because it will reduce the
risk of arrhythmia during and after bronchoscopy [7].
However, even though severe CO2 retention may occur
during the procedure, oxyhemoglobin desaturation may
not be observed. Chhajed et al. [3] have performed cuta-
neous carbon dioxide tension (PcCO2) measurements in
addition to the oxymetry in patients that underwent FB
in which sedation was achieved with intermittent intra-
venous midazolam and 5 mg of hydrocodone, and deter-
mined an increase in PcCO2 in all but one patient. The
highest PcCO2 value was significantly associated to the
Table 1 Demographics and clinical and bronchoscopic
characteristics of patients
Variables All patients (n = 140)
Age, y 58.1 ±13.5
Male gender, n (%) 102 (72.9)
Patients with COPD, n (%) 44 (31.4)
History of smoking, n (%) 73 (52.1)
Smoking pack years 38.4 ±22.4
Duration of bronchoscopy (min) 15.9 ±6.1











Figure 1 Comparison of pre- and post-bronchoscopy
respiratory muscle strength. MIP, Maximum inspiratory pressure;
MEP, Maximum expiratory pressure; *, p < 0.001.
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baseline PcCO2 (p < 0.0001) and lowest SpO2 (p = 0.016).
Dreher et al. [4] have utilized PcCO2 measurements in
order to evaluate alveolar hypoventilation in patients
with pre-existing respiratory failure, and determine a sig-
nificant increase in PcCO2 during the procedure. In their
study, while no significant difference was determined in
terms of PcCO2 during FB between the groups where
the patients were sedated with either midazolam alone
or midazolam plus alfentanil, PcCO2 was higher compared
to baseline in the midazolam alone group 120 minutes
after the procedure than the midazolam plus alfentanil
group. The cause for prolonged hypoventilation was con-
sidered to be midazolam due to the fact that the midazo-
lam alone group received twice the amount of midazolam
than the midazolam plus alfentanil group (4 mg vs. 2 mg).
We believe that the decrease in both the inspiratory and
expiratory respiratory muscle strengths, which was deter-
mined in the high-dose (0.05 ± 0.03 mg/kg) midazolam
group in our study, might play an important role in
hypoventilation that has been determined in the two
studies mentioned above. However, because we did not
measure PcCO2 in our study, we do not know whether
there was an increase in the CO2 values or not, and thus,
we do not know whether the determined muscle weak-
ness has any clinical importance or not.
The effects of midazolam on respiratory muscle
strength have been previously shown in experimental
and clinical studies. Fujii et al. [11] have investigated the
effects of midazolam and propofol on diaphragm con-
tractility in dogs. In that study, they have induced dia-
phragmatic fatigue with intermittent supramaximal
bilateral electrophrenic stimulation at low or high fre-
quency (20 and 100 Hz, respectively), and after the
induction of fatigue, in order to assess the diaphragm
contractility, transdiaphragmatic pressure (Pdi) and inte-
grated electrical activity of the crural (Edi-cru) and costal
(Edi-cost) parts of the diaphragm were measured. Their
findings showed that midazolam caused a decrease in
Pdi at both frequencies when compared to fatigued
values (p < 0.05), and that Edi-cru and Edi-cost at 100 Hz
stimulation during midazolam administration were below
the baseline values (p < 0.05). They have also reported a
lower Pdi value in the midazolam group than in the pro-
pofol group (p < 0.05).
Table 2 Comparison of the differences in pre- and post-procedure maximum respiratory pressures (Δ: pre-post)
between different patient groups
N Δ MIP (pre-post) Δ MEP (pre-post)
Mean± SD (cmH2O) p Mean± SD (cmH2O) p-value
Age (years)
<60 69 2.7 ±16.4 NS 10.0 ±22.61 NS
≥60 71 7.2 ±14.8 10.0 ±15.7
Smoking
Non-smoker 67 6.2 ±16.5 NS 9.8 ±14.8 NS
Smoker 73 3.9 ±14.9 10.2 ±22.7
COPD
No 96 5.4 ±15.7 NS 11.2 ±21.4 NS
Yes 44 4.2 ±15.9 7.4 ±13.5
Duration of bronchoscopy (min)
<15.5 69 4.5 ±16.6 NS 10.2 ±20.0 NS
≥15.5 71 5.5 ±15.0 9.9 ±18.8
Midazolam group
A 34 0.4 ±16.0 <0.001 6.2 ±16.0 <0.05
B 66 1.8 ±13.4 7.8 ±17.6
C 40 14.2 ±15.6* 16.8 ±22.9**
*Via post-hoc analysis, pair-wised comparison of Group C with both Group A and B (p< 0.001 for both). ** Via post-hoc analysis, pair-wised comparison of Group C
with Group A (p = 0.04) and Group B (p = 0.05).
Table 3 Comparison of pre- and post-flexible bronchoscopy MIP and MEP values in different midazolam dose groups
MIP (cm H2O) p MEP (cm H2O) P
Pre Post Pre Post
Group A 80.5 ±25.2 80.0 ±24.7 NS 109.4 ±27.6 103.2 ±21 =0.03
Group B 69.3 ±23.1 67.6 ±22.8 NS 93.6 ±30.3 85.8 ±29.0 =0.001
Group C 75.9 ±24.9 61.7 ±26.6 <0.001 102.1 ±28.9 85.3 ±28.9 <0.001
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In another study, the effects of sedative (0.1 mg/kg/h)
and anesthetic (0.5 mg/kg/h) dosages of midazolam on
the decrease in diaphragm contractility, fatigue (detail
fatigue rating [DFR]), have been evaluated in dogs [12].
They showed that an infusion of midazolam has caused a
decrease from baseline values (p < 0.05) in Pdi at 20 and
100 Hz stimulations, and that%Edi-cru and % Edi-cost
values at 100 Hz were below baseline (p < 0.05) in both
sedative and anesthetic groups. They have also demon-
strated that the Pdi and % Edi decrease was greater in
the anesthetic dose group than in the sedative dose
group (p < 0.05). Their findings show that contractility of
fatigued diaphragm dose-dependently decreases with
midazolam.
Molliex et al. [13] have studied the effects of midazo-
lam, with a dosage of 0.1 mg/kg, on total pulmonary
resistance and diaphragmatic, intercostal and abdominal
muscle patterns in 9 healthy volunteers. Changes in gas-
tric pressure (ΔPga) and pleural pressure (ΔPpl) were
measured in all participants, and the reduction in dia-
phragm contractility was evaluated with ΔPga/ ΔPpl.
Midazolam was determined to increase total pulmonary
resistance in sedative doses, and associatively, an increase
in intercostal muscle activity was also determined;
however, the diaphragmatic contribution to respiratory
process was found to be decreased. This was explained
as a shift from an abdominal breathing to predominantly
rib cage breathing rather than a decrease in diaphragm
contractility. Even though upper airway measurements
were not taken in the current study, the increase in pul-
monary resistance is thought to be associated with upper
airway occlusion. Diazepam causing a decrease in the
activity of the genioglossus muscle, which has an
important role in maintaining the patency of the upper
airway, supports this hypothesis [14].
It is known that bronchoscopy deleteriously affects
pulmonary mechanics and lung volumes [10,15]. This
may arise a question regarding whether the significant
reductions in maximal pressures are related to lung
volumes rather than muscle weakness or respiratory
muscle strength. MIP is measured at or close to RV and
MEP at or close to TLC. Sometimes these measurements
were performed at functional residual capacity. Although
the latter may be more accurate for some studies, in that
case the lung volumes should be specifically stated [16].
In patients with abnormally high lung volumes, a low
MIP may partly reflect the shortened inspiratory muscle
fiber length associated with increased lung volume at RV
rather than reduced inspiratory muscle strength; how-
ever, in our study all moderate to very severe COPD
patients were not taken into the study and also the
groups were not different regarding the number of mild
COPD patients. Therefore it may be considered that the
reductions in maximal pressures are probably not related
to lung volumes.
Although there is limited falls in MEP values in
patients who were not sedated during bronchoscopy,
when Δ MEP values were compared between groups,
the post-hoc analysis revealed that the difference was sta-
tistically significant only with group A and C and the
decline in MEP values was higher in the high-dose mida-
zolam group. When pre and post MEP values within
each group were compared, post MEP values in group B
and C were significantly lower than group A. It is notable
that although post MIP values were significantly lower
only in Group C, there were remarkable falls in post
Table 4 Comparison regarding patient demographics, bronchoscopic characteristics and pre-procedure maximum
respiratory pressures among different midazolam dose groups
Group A (n: 34) Group B (n: 66) Group C (n: 40) p
Male gender, n (%) 24 (70.6) 53 (80.3) 25 (62.5) NS
Age 58.9 ±11.8 55.9 ±14.5 60.9 ±12.8 NS
Patients with COPD, n (%) 14 (41.2) 21 (31.8) 9 (22.5) NS
Smoking pack years 27.6 ±11.6 38.9 ±18.9 36.9 ±21.9 NS
Duration of bronchoscopy (min) 15.5 ±5.9 15.6 ±5.4 16.9 ±7.3 NS
Complications
Tachycardia 19 31 12 NS
Bradycardia 1 1 0 NS
Hypotension 0 1 0 NS
Hypertension 5 5 3 NS
Desaturation 2 1 1 NS
Patient comfort 76.2 ±17.4 74.4 ±17.4 88.1 ±12.5* <0.001
MIP 1 (cmH2O) 80.5 ±25.2 69.3 ±23.1 75.9 ±24.9 NS
MEP 1 109.4 ±27.6 93.6 ±30.1 102.1 ±28.9 NS
* When compared to Groups A and B using the post-hoc test: p < 0.001.
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MEP values in all groups. The fall in post MEP values
even in group A, i.e. in groups who were not sedated with
midazolam might be due to exhaustion of the patient
after repeated maneuvers for correct MIP measurements.
Even though the overall bronchoscopy comfort scores
were quite high in our study, the fact of significantly
higher VAS scores of the patients in the high-dose rather
than in the low-dose midazolam group, and of the simi-
larity of the patient comfort levels in the low-dose and
no midazolam groups can be explained by the bronch-
oscopist’s tendency to administer low doses. It is known
that objective techniques, such as electroencephalogram-
based bispectral index [17] or Ramsay sedation score [18],
allow a more effective titration of the sedatives. In
addition, it is also shown that both inter-individual and
intra-individual variations are seen in the online sedation
monitoring in healthy volunteers who were sedated with
midazolam [19]. This condition may explain why some
patients needed high doses and some low doses of mida-
zolam in our study although the bronchoscopist decided
the appropriate sedation level in patients subjectively. In
humans, midazolam is mostly metabolized by CYP3A4⁄5
isozymes to one major metabolite, 1-hydroxymidazolam
and to some extent to 4-hydroxymidazolam and 1,4-
dihydroxymidazolam [20,21]. It is well known that wide
inter-individual variations in hepatic and intestinal CYP3A
activity are seen in the human population [22].
Conclusion
In conclusion, midazolam for premedication purposes
has been determined to increase comfort in patients
undergoing flexible bronchoscopy, however, causing sig-
nificant decrease in respiratory muscle strength. This
might increase the probability of possible complications
following bronchoscopy in critical patients who have
advanced COPD with limited respiratory reserves or
respiratory insufficiency. Certainly there is a special
need for further studies with risk patient groups and the
use of high-dose midazolam.
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